FDA approved the new drug ERAVACYCLINE in August 2018
On August 29, 2018, Tetraphase Pharmaceuticals announced that the US FDA approved XERAVATM (eravacycline) for the treatment of complex intra-abdominal infections (cIAI). In clinical trials, eravacycline is well tolerated and exhibits a high clinical cure rate in cIAI patients. It achieves statistical non-inferiority compared to two widely used antibiotics, ertapenem and meropenem.
Intraperitoneal infection (IAI) is a common clinical problem, including a variety of disease processes. According to the degree of infection, IAI is divided into simplicity or complexity. Due to perforation or other damage to the gastrointestinal tract, the complex IAI (cIAI) extends beyond the source organ into the peritoneal space (the space between the two membranes separating the organs in the abdominal cavity from the abdominal wall). cIAI diagnosis includes intra-abdominal abscess, gastric or intestinal perforation, peritonitis, appendicitis, cholecystitis or diverticulitis. A variety of bacterial pathogens can cause cIAI, including Gram-negative aerobic bacteria, Gram-positive bacteria, and anaerobic bacteria. Early detection, control, and appropriate antibacterial therapy are critical to the successful treatment of cIAI. This becomes more important as the rate of infection caused by resistant bacteria increases, as this limits the effectiveness of currently available antibiotics.
Send inquiry online For more product information and prices
(Pharmaceutical Ingredients Manufacturer & Supplier & Exporter.)
After sending the online inquiry, we will reply you as soon as possible, if not get any response on time please contact us by Tel or Email. —— Green Stone SwissEmail: [email protected]
Tel: +86 592 5365887
WhatsApp: +86 189 6515 7632
Send inquiry online: